Pemetrexed maintenance with or without pembrolizumab in non-squamous non-small cell lung cancer: A cross-trial comparison of KEYNOTE-189 versus PARAMOUNT, PRONOUNCE, and JVBL

Keyphrases

• Pemetrexed 100%
• Non-squamous Non-small Cell Lung Cancer 100%
• Pembrolizumab 100%
• CROSS Trial 100%
• KEYNOTE-189 100%
• 5-cycle 29%
• Confidence Interval 23%
• Placebo 23%
• Progression-free Survival 17%
• Median Progression-free Survival 11%
• Treatment-related Adverse Events 11%
• Maintenance Data 11%
• Hazard Ratio 5%
• Historical Data 5%
• Safety Profile 5%
• Tumor Grade 5%
• Cox Proportional Hazards Model 5%
• Kaplan-Meier Estimator 5%
• Control Arm 5%
• Comparative Analysis 5%
• Tumor Response 5%
• Patient Selection 5%
• Treatment Setting 5%
• Descriptive Statistics 5%
• Risk-benefit 5%
• Objective Response Rate 5%
• Selected Populations 5%
• Survival Profile 5%

Medicine and Dentistry

• Non Small Cell Lung Cancer 100%
• Pemetrexed 100%
• Pembrolizumab 100%
• Comparison Trial 100%
• Arm 29%
• Progression Free Survival 29%
• Placebo 23%
• Adverse Event 11%
• Neoplasm 5%
• Hazard Ratio 5%
• Proportional Hazards Model 5%
• Kaplan Meier Method 5%

Pharmacology, Toxicology and Pharmaceutical Science

• Non Small Cell Lung Cancer 100%
• Pemetrexed 100%
• Pembrolizumab 100%
• Comparison Trial 100%
• Progression Free Survival 29%
• Placebo 23%
• Adverse Event 11%
• Neoplasm 5%